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Commentary  
Implications for practice and research  
 
• The secondary use of statins is effective in reducing the absolute 
risk of ischemic stroke and cardiac events in patients who have 
previously had an ischemic stroke or transient ischemic attack. 
 
• There is still uncertainty about which statin is the most effective.  
 
 
Context 
 
Stroke is one of the major causes of worldwide death and disability with one in four 
people predicted to experience a stroke within their lifetime (1). After a stroke or a 
Transient Ischemic Attack [TIA] there remains a substantial long-term risk of 
recurrent stroke (2). It is recommended that statins should be used to reduce the risk 
of recurrent stroke with ischemic stroke or TIA presumed to be of atherosclerotic 
origin (3). This review aimed to summarize the current evidence on the benefits and 
harms of the varying statins used for secondary prevention for these patients (4). 
  
Methods 
 
The review carried out a comprehensive literature search on multiple databases from 
January-2008 to July-2017. Studies prior to 2008 were identified through two 
Cochrane systematic reviews. Only randomised controlled trials [RCTs] which 
compared any single statin compared to placebo/no statin or another statin in adults 
with stroke or TIA from all clinical settings were included. A robust screening 
process, data extraction and quality assessment (Cochrane collaboration criteria and 
GRADE) was carried out by two independent reviewers with arbitration by a third 
reviewer. An appropriate synthesis was carried out using a pairwise and network 
meta-analyses, and trial sequential analyses.  
 
 
 
Findings 
 
Four different statins (Atorvastatin, Simvastatin, Rosuvastatin and Pravastatin) were 
compared to placebo/no statin. The review found that there was not strong evidence 
to indicate that one statin was better than the other for the outcomes assessed within 
this review.  Atorvastatin 80mg/day appeared to have a statistically significant benefit 
for risk of ischemic stroke, ischemic stroke & TIA and cardiovascular events and 
Simvastatin 40mg/day appeared to have a statistically significant benefit for risk of 
cardiovascular events. 
 
There was not strong evidence that statins have an effect on reducing the risk of 
stroke (ischemic or hemorrhagic), all cause-mortality, hemorrhagic stroke and rise in 
creatine kinase compared to placebo/no statin.  
 
There was high quality evidence that statins statistically and clinically significantly 
reduced the risk of ischemic strokes and cardiac event. 
 
For both outcomes of risk of ischemic attack and cardiac events, the authors of the 
review have a lot of confidence that the true effect is similar to the estimated effect. 
The estimated effect from this review result in the number needed to treat being 63 
(95%.CL,39-167) patients to prevent one additional ischemic attack and 19 
(95%.CL,15-28) people to prevent one additional cardiac event. These findings are 
similar to other published systematic reviews for these outcomes and are clinically 
significant. 
  
 
Commentary  
 
This review is of high quality and provides an accurate and comprehensive summary 
of the results of the available studies that address the question of interest. The 
findings from this review were limited by there being a lack of evidence in specific 
outcomes and no head-to-head comparisons of statins which has resulted in some 
of the comparisons being underpowered. Furthermore, there was also a scarcity of 
evidence for patients who were at high risk which result in these findings being less 
applicable for this subpopulation. 
 
When choosing statins for a secondary preventative measure for people who have 
had a stroke, there is currently limited evidence to indicate for the outcomes 
assessed in this review one over the other. Where these uncertainties still exist, 
there are other important aspects which can be taken into consideration when 
deciding which statin to use such as patient preference, pharmacokinetic properties, 
safety, cost and patient characteristics (3)..  
 
For the outcomes of the risk of all stroke, all cause-mortality, hemorrhagic stroke, 
rise in creatine kinase and the effect of stroke subtypes at inclusion, treatment dose, 
time from the first ischemic event to randomization there is still uncertainty. Based on 
this uncertainty there is a requirement for further research on these outcomes, 
specifically regarding the effect on the risk of hemorrhagic stroke as there seems to 
be the greatest uncertainty around this outcome. 
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